T he article by Scotland et al 1 published in this issue of Circulation reports on a unique mouse model that might help to identify a longstanding, intensely investigated, and controversial substance called endotheliumderived hyperpolarizing factor (EDHF). EDHF is a "holy grail," a "third factor" that provides local control of vascular homeostasis in addition to nitric oxide (NO) and prostacyclin. The discovery of the latter substances, which are known to cause both hyperpolarization and relaxation, led to Nobel prizes. But beware acronyms! The term EDHF is Ͼ15 years old, and as yet no one substance and no one mechanism has been proposed that explains all of its features. The story of the investigation has been a meandering one, with many stops along the way. Each stop has taught us how blood vessels function, but there is more to be learned if we are to have a complete understanding.
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Twenty-five years ago, Robert Furchgott identified that acetylcholine and bradykinin generated a diffusible, shortlived mediator from endothelial cells that relaxed underlying smooth muscle cells by a mechanism similar to that of nitrovasodilators. 2 This seminal observation led to the identification of the substance as NO, contributed in a major way to the growth of vascular biology, 3 and increased our understanding of why cardiovascular risk factors and disease diminish vasodilatation. Notwithstanding the importance of NO and cyclic guanosine monophosphate (cGMP), the major intracellular mediator of NO-induced smooth muscle relaxation, many of us in the field have had the nagging feeling that something was missing. 4 That this feeling is warranted is no better exemplified than by the findings of Scotland et al. 1 These authors show that transgenic mice devoid of endothelial NO synthase (eNOS) and cyclooxygenase (COX)-1 maintain a mechanism by which acetylcholine can hyperpolarize, relax, and vasodilate resistance blood vessels. Because their experimental strategy seemingly excludes the enzymatic sources of NO and prostacyclin, the authors conclude that a non-NO, nonprostacyclin substance must be involved. Furthermore, they make the fascinating observation that the mechanism shows a marked gender preference for female mice. To help the reader put the authors' observations in perspective, I would like to briefly discuss their findings in relationship to our prior knowledge and current understanding of EDHF and to suggest potential fruitful areas of investigation. Scotland et al 1 review the pertinent literature, and the subject of EDHF has been reviewed in depth in Circulation by this author and a colleague, 4 and more recently by leaders in the field. 5
What Is EDHF and What Is Its Endothelial Source?
Since the original description that the endothelium-dependent vasodilator acetylcholine causes smooth muscle hyperpolarization 6 (and, hence, coining of the term EDHF 7 ), considerable research has been done to identify a factor that, like NO, diffuses from the endothelium and hyperpolarizes the smooth muscle cell. Hyperpolarization is thought to promote relaxation by inhibiting voltage-dependent calcium channels, although there are other possibilities. 4 Despite the research, no consensus has been reached as to the mediator of endothelium-dependent hyperpolarization or its mechanism of action. It has always been assumed that the mediator and mechanism of EDHF supplements the actions of NO and prostacyclin, both of which are confirmed endothelium-derived hyperpolarizing and relaxing factors. 4, 8 Indeed, vascular hyperpolarization and relaxation in the presence of inhibitors of NOS and COX-1 have been taken to be synonymous with EDHF. Scotland et al 1 show that these inhibitors leave a substantial portion of the mesenteric artery relaxation to acetylcholine or bradykinin intact. By showing that the aortic relaxation to acetylcholine is blocked by the same inhibitors, they also demonstrate another characteristic of EDHF. Although some large arteries, in particular, pig, bovine, and human coronary arteries, have potent EDHF mechanisms, this mechanism appears to be most important in small arteries that account for vascular resistance and therefore blood pressure regulation. NO was in part identified as a short-lived endothlium derived relaxing factor (EDRF) by its ability to diffuse from an artery with intact endothelium and to relax a neighboring artery denuded of endothelium. Unfortunately, except under special circumstances, inhibitors of NOS and COX-1 block the substantial relaxing factor present in the perfusate of arteries with intact endothelium. 4, 5, 9 This leaves open the possibility that EDHF is even more short-lived than NO or that it is present in too low a concentration to function in such an experiment. Nevertheless, the hyperpolarization and relaxation of arteries, which persist in the presence of NOS and COX-1 inhibitors, bear some resemblance to EDRF. The response requires an intact endothelium and an increase in endothelial intracellular Ca 2ϩ levels, which activates a calmodulin-dependent mechanism similar to that required for eNOS. 10 Derivatives of endothelial cell arachidonic acid have been suspected to be EDRF even since the first report, 2 and this possibility is compatible with increased activity of Ca 2ϩ -dependent phospholipase A 2 , which releases large amounts of arachidonic acid from endothelial cells stimulated by acetylcholine or bradykinin. Inhibitors of cytochrome P450, a major pathway of nonprostanoid arachidonic acid metabolism, were recognized early on to inhibit endothelium-dependent relaxation, and products of this enzyme, eicosatetraenoic acids (EETs), were shown to directly activate potassium channels and to cause smooth muscle cell hyperpolarization and relaxation. The difficulty of bioassaying a diffusable hyperpolarizing or relaxing factor in the presence of NOS and COX-1 inhibitors has led to the conclusion that although EETs may be involved, they may instead act primarily on endothelial cell potassium channels to hyperpolarize that cell. Unlike smooth muscle cells, endothelial cells are devoid of typical voltage-sensitive Ca 2ϩ channels, and hyperpolarization promotes Ca 2ϩ entry into the cell through nonselective ion channels. This in turn may further stimulate as-yet unidentified Ca 2ϩ -dependent processes in the endothelium that promote vascular relaxation. One interesting proposal is that opening of endothelial K ϩ channels, perhaps mediated by EETs, allows for the efflux of potassium from endothelial cells in sufficient amounts that it hyperpolarizes the smooth muscle cells. 5 This suggestion depends on endothelium-dependent smooth muscle cell hyperpolarization occurring via inward rectifier potassium channels and Na ϩ /K ϩ ATPase, both of which are stimulated by low concentrations of K ϩ . K ϩ as an EDHF remains a possibility, and its dilution in solution may explain why it is difficult to bioassay. Nevertheless, identification of a non-NO, nonprostanoid factor that is released from endothelial cells in sufficient amounts to cause smooth muscle hyperpolarization is lacking. What explains the fact that after 20 years of investigation, no factor has been found?
One issue is that many of the experimental observations have necessarily required the use of pharmacological inhibitors that may not block 100% of the intended target or that lack specificity. For instance, cytochrome P450 inhibitors used in early experiments were later shown to block potassium channels. Also, NOS inhibitors, which have been widely used to exclude the role of NO, may not completely inhibit NO release, and their efficacy has rarely been verified. As an example, 8 years ago my colleagues and I were in the midst of investigating the mechanisms of endothelium-dependent relaxation of the rabbit carotid artery. This blood vessel has all of the typical characteristics of EDHF, including endothelium-dependent hyperpolarization and relaxation that persist in the presence of NOS and COX-1 inhibitors, 11 which are blocked by K ϩ channel and cytochrome P450 inhibitors. Using 2 separate methods of measurement, we made the striking finding that despite using high concentrations of NOS inhibitors, almost 30% of the release of nitric oxide persisted, and the hyperpolarization and relaxation of the artery in the presence and absence of the NOS inhibitors correlated with NO release. 8 This may simply be because the NOS inhibitors that are generally used are competitive antagonists that by their nature do not provide insurmountable blockade of arginine use by NOS. Also, smaller arteries with EDHF-like properties such as the rabbit carotid artery release higher amounts of NO that are more difficult to block with inhibitors. 12 Scotland et al 1 appear to have circumvented any possibility that they did not prevent the release of NO or prostacyclin because they used genetic deletion of both the enzymes that normally produce them. They demonstrated that prostacyclin release was diminished in the blood of the mice they studied. They did not, however, evaluate whether NO was eliminated. This possibility would seem to be unlikely were it not for a series of elegant studies by Meng et al, 13 who showed that in small cerebral pial blood vessels of the eNOS-deficient mouse, endothelium-dependent vasodilation persists. These authors showed that through a striking demonstration of genetic flexibility, the persistent responses are mediated by the other calcium-dependent NOS isoform, neuronal NOS (nNOS), that replaces the deleted eNOS in the endothelium. 13 Although neither the authors nor the reviewers of the article by Scotland et al 1 appear to have been aware of this work, Scotland et al did show that addition of NOS inhibitor to the arteries deficient in eNOS had no further effect. Although this should obviate any possibility that release of NO persists, nNOS is particularly difficult to completely inhibit, and it is possible that nNOS is producing something other than NO that is unimpeded by NOS inhibitors. 14 Finally, the female gender preference for the EDHF response is compatible with an increased expression of nNOS caused by estrogen. 15 Until recently, the possibility that NOS could produce a mediator other than NO that could function as an EDHF would have seemed unlikely. Like Scotland and associates, however, Matoba et al 16 showed that hyperpolarizing responses to acetylcholine of mouse mesenteric arteries resisted NOS and COX-1 inhibitors and persisted in eNOS-deficient mice. They showed that catalase inhibited acetylcholineinduced hyperpolarization and relaxations that persisted in the presence of the NOS and COX-1 inhibitors in wild-type mice, and proposed that hydrogen peroxide produced by eNOS is EDHF. Morikawa et al 17 provided evidence that strengthened the prospects that hydrogen peroxide may be a NOS-derived vasodilator by showing that mice deficient in Cu/Zn superoxide dismutase, which catalyzes the formation of hydrogen peroxide from superoxide anion, display diminished EDHF vascular responses. They concluded that superoxide dismutase may be an "EDHF synthase." In our own studies, we found that the rabbit carotid artery still relaxed to acetylcholine, despite blocking superoxide dismutase activity. 12 As expected, however, this relaxation greatly increased superoxide levels and decreased the ability of NO to stimulate cGMP. This suggests the possibility that NO released from NOS reacts with superoxide anion to form the product peroxynitrite, which might constitute another mediator of relaxation. 12 Further research is required to determine the precise role of hydrogen peroxide, peroxynitrite, and perhaps other reactive oxygen and nitrogen species as EDHF.
Cohen
The EDHF Puzzle: A Mechanism Without a Mediator?
How Does EDHF Relax Vascular Smooth Muscle?
For NO, the simple view is that relaxation of smooth muscle occurs through the stimulation of guanylyl cyclase to produce its product, cGMP, which causes multiple protein kinase G substrates to decrease intracellular Ca 2ϩ and inhibit contractile proteins to relax smooth muscle. For EDHF, without knowing precisely what the mediator is, it is difficult to define precisely how hyperpolarization of the smooth muscle occurs. Nevertheless, inward rectifier K ϩ channels and Na ϩ /K ϩ ATPase were identified and shown by the use of barium and ouabain, respectively, to play a role in endothelium-dependent hyperpolarization. Scotland et al 1 show that these inhibitors, and, in addition, removal of the endothelium, prevent the residual relaxations in the mesenteric arteries of mice deficient in NOS and COX-1. Another important mechanism by which endothelial cells cause smooth muscle hyperpolarization arose when it was realized that electrical conductance can occur directly from endothelium to smooth muscle. An anatomic feature called "gap junctions," formed between the cells by connexin proteins, underlie this property. They are present particularly in small arteries where the apposition of the 2 cells is closest, potentially explaining the larger role for EDHF in small arteries. Inhibitors of gap junctions block the hyperpolarization caused by acetylcholine in smooth muscle cells of guinea pig mesenteric arteries without blocking the hyperpolarization of the endothelium, suggesting the importance of this mechanism. 18 Thus, EDHF may not be an enzymatically derived "factor" that, like NO and prostacyclin, diffuses from endothelial cells to smooth muscle; rather it may be a phenomenon that begins as a calcium-activated event that hyperpolarizes the endothelium and a signal that is transferred to the smooth muscle by K ϩ or via gap junctions. The endothelial hyperpolarization could be initiated by EETs or NOS-derived NO, hydrogen peroxide, peroxynitrite, or other reactive species.
As mentioned above, the hyperpolarization and relaxation of the rabbit carotid artery persist in the presence of NOS and COX-1 inhibitors but can be explained by the NO release that persists. More striking is that despite the residual NO, the NOS inhibitors largely prevent the rise in smooth muscle cGMP, suggesting that NO may mediate hyperpolarization and relaxation of the smooth muscle by other means. One possibility is that NO can activate K ϩ channels by a thiol redox-dependent mechanism. 19 Another is that NO may regulate other mechanisms of membrane potential regulation such as Na ϩ /K ϩ ATPase. Still another is that NO, without the aid of cGMP, increases the activity of the sarco(endo)plasmic reticulum Ca 2ϩ ATPase (SERCA). This in turn increases intracellular stores of Ca 2ϩ , resulting in the closing of storeoperated, nonselective ion channels. 20 Because these channels conduct Na 2ϩ in addition to Ca 2ϩ , their closing hyperpolarizes the smooth muscle cell membrane. We recently demonstrated the molecular mechanism by which NO activates SERCA via formation of peroxynitrite within smooth muscle cells, which in turn S-glutathiolates reactive cysteine thiols on SERCA. 21 Indeed, SERCA was S-glutathiolated during endothelium-dependent relaxation of the rabbit carotid artery, consistent with this mechanism.
Where Do We Go From Here?
This story, like any search for a holy grail, is long and complex, but I think it is fair to conclude that much productive research has been performed in pursuit of the goal of more fully understanding the mechanisms of vasodilatation. Clearly, the story goes well beyond NO and cGMP. 4 Other mediators, including NOS-derived reactive oxygen and nitrogen species, as well as arachidonic acid derivatives, are likely to be involved. We have moved well beyond the simple concept of diffusable endothelial factors to a need for deeper understanding of the mechanisms by which endothelial cell Ca 2ϩ is regulated and by which endothelial membrane potential is regulated and transmitted to the smooth muscle. The mechanisms by which smooth muscle relaxes involve multiple pathways, and an integrated approach is required to fully understand vasodilation. Such an experimental approach requires new methodologies to monitor not only Ca 2ϩ but also K ϩ , Na ϩ , and Cl Ϫ ions, along with membrane potential and vessel diameter. New concepts of redox regulation by reactive oxygen and nitrogen species need to be integrated with our knowledge of the function of ion channels and transporters, as well as contractile proteins. The physiological responses must be correlated with measurements of the suspected mediators, whether they be intra-or extracellular, so that their role is validated.
With good reason, Scotland et al 1 suggest that the mouse model that they have created provides an excellent model with which to identify and further understand EDHF. They provide evidence that without eNOS or COX-1 a major mechanism of blood pressure control remains that counters the hypertension that is expected from the lack of eNOS. Understanding the mechanism is a worthy goal with great potential for the development of therapeutics, particularly for systemic and pulmonary hypertension. Scotland et al provide the "teaser" that the vasodilator mechanism observed in their female double-knockout mice might help to explain the relative cardioprotection enjoyed by women. If this is true, then their findings will have epidemiological importance as well.
